<SEC-DOCUMENT>0001209191-23-017833.txt : 20230310
<SEC-HEADER>0001209191-23-017833.hdr.sgml : 20230310
<ACCEPTANCE-DATETIME>20230310164956
ACCESSION NUMBER:		0001209191-23-017833
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230309
FILED AS OF DATE:		20230310
DATE AS OF CHANGE:		20230310

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Azoy Alexander
		CENTRAL INDEX KEY:			0001771961

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		23724399

	MAIL ADDRESS:	
		STREET 1:		30699 RUSSELL RANCH ROAD, SUITE 140
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2023-03-09</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001724521</issuerCik>
        <issuerName>Arcus Biosciences, Inc.</issuerName>
        <issuerTradingSymbol>RCUS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001771961</rptOwnerCik>
            <rptOwnerName>Azoy Alexander</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ARCUS BIOSCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>3928 POINT EDEN WAY</rptOwnerStreet2>
            <rptOwnerCity>HAYWARD</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94545</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Accounting Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>690</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>216</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>3187</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2375</value>
                    <footnoteId id="F3"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5128</value>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>21.53</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F5"/>
            </exerciseDate>
            <expirationDate>
                <value>2030-11-07</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>87500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>31.49</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F6"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-03-07</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>867</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>33.03</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F7"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-03-08</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>8500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>22.02</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F8"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-01-22</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>9500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents restricted stock units that were granted on March 8, 2021. The remaining RSUs will vest in two equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.</footnote>
        <footnote id="F2">Represents restricted stock units that were granted on March 8, 2022. The remaining RSUs will vest in three equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.</footnote>
        <footnote id="F3">Represents restricted stock units that were granted on December 15, 2022. The remaining RSUs will vest in two equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.</footnote>
        <footnote id="F4">Represents restricted stock units that were granted on January 23, 2023. The remaining RSUs will vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.</footnote>
        <footnote id="F5">This option was granted on November 9, 2020, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 45,833 of the shares of common stock subject to this option were exercisable.</footnote>
        <footnote id="F6">This option was granted on March 8, 2021, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 470 of the shares of common stock subject to this option were exercisable.</footnote>
        <footnote id="F7">This option was granted on March 8, 2022 with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 2,479 of the shares of common stock subject to this option were exercisable.</footnote>
        <footnote id="F8">This option was granted on January 23, 2023, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 396 of the shares of common stock subject to this option were exercisable.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Carolyn Tang, Attorney-in-Fact</signatureName>
        <signatureDate>2023-03-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poa.txt
<DESCRIPTION>POA DOCUMENT
<TEXT>
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

The undersigned, as a Section 16 reporting person of Arcus Biosciences, Inc., a
Delaware corporation (the "Company"), hereby constitutes and appoints each of
Terry Rosen, Ph.D., Juan C. Jaen, Ph.D., Carolyn Tang, Nicholas Griffin, Jason
Barker, Jennifer Yip, Kenneth Guernsey and Brett White signing individually, the
undersigned's true and lawful attorney-in-fact to:

1. complete and execute Form ID, "Update Passphrase Confirmation" form and Forms
3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact
shall in his or her discretion determined to be required or advisable pursuant
to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules
and regulations promulgated thereunder, or any successor laws and regulations,
as a consequence of the undersigned's ownership, acquisition or disposition of
securities of the Company; and

2. do all acts necessary in order to file such forms with the Securities and
Exchange Commission, any securities exchange or national association, the
Company and such other person or agency as the attorney-in-fact shall deem
appropriate.
The undersigned hereby grants to the attorneys-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary or
proper to be done in the exercise of any of the rights and powers herein granted
and hereby ratifies and confirms all that said attorneys-in-fact and agents
shall do or cause to be done by virtue of this Power of Attorney. The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with the
Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of March 9, 2023.

By: /s/ Alexander Azoy
Name: Alexander Azoy

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
